DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS (Notes)

3 Months Ended

Mar. 31, 2021

Acquisitions, Divestitures and Other Arrangements [Abstract]

Divestitures, Licensing and Other Arrangements [Text Block]

DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS

Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).

	Three Months Ended March 31,
	Net Proceeds(a)				Divestiture Gains				Royalty Income
Dollars in Millions	2021		2020		2021		2020		2021		2020
Diabetes Business	$	164	$	153	$	—	$	—	$	(134)	$	(127)
Erbitux* Business	—		4		—		—		—		—
Manufacturing Operations	—		—		—		(1)		—		—
Plavix* and Avapro*/Avalide*	5		7		—		(12)		—		—
Mature Brands and Other	11		31		—		(3)		(1)		(31)
Total	$	180	$	195	$	—	$	(16)	$	(135)	$	(158)

(a)    Includes royalties received subsequent to the related sale of the asset or business.

Licensing and Other Arrangements

The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, up-front and milestone licensing fees for products that have not obtained commercial approval, which are included in Other (income)/expense, net.

	Three Months Ended March 31,
Dollars in Millions	2021		2020
Keytruda* royalties	$	(192)	$	(161)
Tecentriq* royalties	(22)		—
Up-front licensing fees	—		(30)
Contingent milestone income	—		(41)
Amortization of deferred income	(15)		(15)
Other royalties	(3)		(5)
Total	$	(232)	$	(252)